Simris Group is making amanitin-based ADCs the center of its strategy under former Heidelberg Pharma CEO Andreas Pahl — less ...

Hanover-based Allogenetics has raised €3.8 million in a Pre-Series A round to advance ALG-115, an ex vivo gene therapy for ...

The European Investment Bank (EIB) is providing German Ethris with €30 million to advance clinical development of its ...

CDMO company Northway Biotech has opened a €61 million cell therapy and personalized medicine center in Vilnius that is being ...

The Barcelona-based biotech will use the financing to complete a 30-patient Phase 2a study of its lead candidate CTH120, with the first efficacy data expected in mid-2027.

Novartis has suffered another pipeline setback after del-desiran, an antibody-oligonucleotide conjugate acquired with Avidity ...

Novartis’ pelacarsen failed to reduce cardiovascular events in the first Phase 3 outcomes trial of an Lp(a)-lowering drug, ...

Pharvaris’ once-daily oral deucrictibant XR reduced hereditary angioedema (HAE) attacks by 83% versus placebo in a pivotal ...

Next-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have ...

A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to ...

Novartis’ remibrutinib has beaten teriflunomide in two Phase 3 trials in relapsing multiple sclerosis (MS), adding another ...

Danish biotech Teitur Trophics completed its phase 1 study and said its experimental Parkinson's disease treatment TT-P34 was safe and reached the central nervous system, supporting plans to move the ...